

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Endocrine disease				
Diabetes	Insulin receptor tyrosine kinase (INSR tyrosine kinase)	<i>In vitro</i> and <i>in vivo</i> studies suggest that a class of phenylamine derivatives are INSR tyrosine kinase activators that might help treat diabetes. In a murine model of streptozotocin-induced diabetes, intraperitoneal or oral delivery of one of the derivatives lowered blood glucose levels compared with the effects of saline control. In cultured mouse adipocytes, the compound plus insulin increased glucose transport activity compared with the effect of insulin alone. Next steps include advancing INSR tyrosine kinase activators into Phase Ib/IIa trials.	Patented for treating type 2 diabetes; licensed to ReceptorBio Inc.	Lum, R.T. <i>et al. J. Med. Chem.</i> ; published online Sept. 13, 2008; doi:10.1021/jm800600v Contact: Joseph L. Evans, ReceptorBio Inc., Foster City, Calif. e-mail: jevansphd@earthlink.net